Pregabalin, sold under the brand name Lyrica, carries a real and growing risk of misuse and addiction, particularly among people with a history of substance use disorders. Originally developed for nerve pain, epilepsy, and generalized anxiety, pregabalin produces calming and sometimes euphoric effects that have made it increasingly attractive for non-medical use. A systematic review found that pregabalin appeared more addictive than its close relative gabapentin, with stronger dependence symptoms and more durable patterns of self-administration among people who misused it.1PubMed. How addictive are gabapentin and pregabalin? A systematic review The scope of the problem has expanded enough that scientific research into pregabalin misuse has surged since 2010, with keywords like “abuse,” “addiction,” and “opioids” appearing together with increasing frequency in the published literature.2PubMed Central. Trends in pregabalin misuse and abuse: A 25-year bibliometric perspective
How Pregabalin Works in the Brain
Pregabalin binds to a specific part of calcium channels in the nervous system, which reduces the release of several chemical messengers, including noradrenaline, serotonin, glutamate, and acetylcholine.3Brain Research. Pregabalin increases food intake through dopaminergic systems in the hypothalamus That broad dampening of nerve signaling is what makes the drug useful for conditions involving overactive nerves, such as neuropathic pain, seizures, and anxiety. But the same calming effect also explains why some people find the drug appealing recreationally. At higher-than-prescribed doses, users often report feelings of relaxation, sociability, and mild euphoria that some compare to the effects of alcohol or benzodiazepines.
Pregabalin reaches peak blood levels faster than gabapentin and is absorbed more predictably, which gives it a quicker onset. That pharmacological profile matters for abuse potential because drugs that hit quickly tend to be more reinforcing. Animal research supports this: in a mouse model, pregabalin prompted voluntary self-administration at higher doses and led to measurable withdrawal behaviors after a period of forced abstinence, including signs consistent with depression and anxiety.4PubMed Central. Oral self-administration of pregabalin in a mouse model and the resulting drug addiction features The same study found that higher-dose animals showed declines in recognition memory, suggesting cognitive effects that parallel what human users sometimes describe.
Who Is Most at Risk
The single strongest predictor of pregabalin misuse is a current or past substance use disorder. The systematic review on gabapentinoid addiction identified the principal at-risk group as patients with other addictions, especially opioid and polydrug users, who tended to prefer pregabalin over gabapentin.5PubMed. How addictive are gabapentin and pregabalin? A systematic review This finding has been borne out in clinical settings. In one study that screened urine samples from people in treatment for opioid addiction, about 12% tested positive for pregabalin even though none of them had a medical reason to be taking it. By contrast, only about 3% of a control group of chronic pain patients tested positive.6PubMed. Pregabalin abuse among opiate addicted patients
That gap underscores a pattern clinicians have recognized for years: pregabalin is not typically the first drug someone misuses. It tends to enter the picture after other substance problems are already established. A qualitative study that interviewed patients about their pregabalin misuse found that most had psychiatric or physical health conditions for which they had not received adequate medical care, leading them to use pregabalin as self-medication for anxiety, depression, or chronic pain.7PubMed Central. Misuse of Pregabalin: a qualitative study from a patient’s perspective That finding complicates the picture: some people who misuse pregabalin are not chasing a high so much as trying to treat symptoms they feel their healthcare system has failed to address.
For people without any history of substance problems who take pregabalin at prescribed doses, the risk of developing addiction appears much lower. But “lower” does not mean “zero.” Case reports have documented withdrawal syndromes in patients with no psychiatric or substance use history, at doses as modest as 150 mg per day and after durations ranging from a few weeks to several years.8PubMed Central. Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review These cases are rare enough to still warrant individual case reports, which tells you they are not common, but they are real enough to take seriously.
The Danger of Mixing Pregabalin with Other Drugs
Most of the serious harm from pregabalin misuse does not come from pregabalin alone. It comes from combining it with other sedating drugs, especially opioids and benzodiazepines. In a large observational series of pregabalin poisoning cases, other substances were involved in roughly 88% of presentations. Sedating drugs were co-ingested in about 79% of cases, with opioids and benzodiazepines being the most common partners.9PubMed Central. Pregabalin poisoning and rising recreational use: a retrospective observational series Coma occurred in about 18% of those presentations, and nearly all of the patients who became deeply unconscious had taken another sedating drug alongside pregabalin. Only a single patient out of hundreds reached that level of sedation from pregabalin alone.
The interaction with opioids is particularly dangerous. Laboratory research in mice showed that even a low dose of pregabalin that did not itself suppress breathing could reverse the body’s tolerance to morphine’s respiratory effects, causing significant breathing depression. At higher doses, pregabalin’s own suppression of breathing added on top of the opioid effect.10PubMed Central. Risk to heroin users of polydrug use of pregabalin or gabapentin That mechanism is especially treacherous for people on long-term opioids who believe they have built up a safe tolerance: adding pregabalin can strip that tolerance away and make their usual opioid dose life-threatening.
Clinical data from real patient populations confirm this laboratory finding. In a nationwide study of patients receiving opioid maintenance treatment, pregabalin prescriptions were associated with a nearly threefold increase in the risk of overdose death.11PubMed. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study A separate review of the evidence across multiple settings estimated that the combination of opioids and gabapentinoids was associated with a hazard ratio of about 3.4 for opioid-related death in maintenance treatment populations, and with modestly elevated odds of respiratory depression in surgical and chronic pain settings.12PubMed. Non-opioid antinociceptive drugs: risk of respiratory depression and death related to concomitant use of gabapentinoids in addition to opioids
Withdrawal and Dependence
People who stop pregabalin abruptly after regular use, whether prescribed or not, can experience a withdrawal syndrome that shares features with both benzodiazepine and alcohol withdrawal. Symptoms tend to cluster into psychiatric problems (anxiety, insomnia, agitation), nervous system effects (tremor, headaches, sweating), gastrointestinal complaints (nausea, diarrhea), and general malaise.13PubMed. Management of Pregabalin Use Disorder: A Case Series In severe cases, seizures have been reported, which is one reason clinicians recommend gradual tapering rather than sudden cessation.
An analysis of Australia’s adverse event reporting database found that pregabalin had strikingly elevated signals for drug abuse and dependence reports compared to all other drugs in the database. It also showed elevated signals for withdrawal reports and, more alarmingly, for suicide and self-injury as well as psychotic disorders.14PubMed Central. Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database When pregabalin was compared specifically to other drugs used for nerve pain rather than to the entire database, the abuse and dependence signal remained present, though the difference was less dramatic. Adverse event databases do have limitations since they rely on voluntary reporting and cannot prove causation, but the sheer magnitude of the signals has caught the attention of regulators.
How Widespread Is Misuse
Global consumption of gabapentinoids rose steeply over the last decade. Across 65 countries representing about 70% of the world’s population, gabapentinoid consumption increased by an average of roughly 17% per year between 2008 and 2018.15Nature Communications. Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study That growth reflects both expanded legitimate prescribing for conditions like neuropathic pain and a parallel rise in non-medical use. Prescribing of pregabalin has been increasing worldwide, and public health concerns have followed accordingly.16Journal of Drug Issues. Pregabalin Misuse and Abuse: A Scoping Review of Extant Literature
Much of the non-medical supply comes from diverted prescriptions, but online markets have become an important channel too. Research on internet sourcing of controlled medicines in the UK has flagged that end consumers purchasing pregabalin online may receive counterfeit pills containing either harmless inactive ingredients or potentially dangerous unknown substances.17Emerging Trends in Drugs, Addictions, and Health. Internet sourcing and UK end consumer trend interest in the controlled medicines (opioids, sedatives and GABA drugs) in pre and post COVID-19 timeframes The unpredictability of counterfeit pills adds a layer of risk that sits on top of pregabalin’s inherent dangers.
What Forensic Evidence Shows
Post-mortem studies have helped establish how pregabalin figures into drug-related deaths. A two-year review of post-mortem blood samples found pregabalin in 70 cases, with about a third of those showing concentrations above the expected therapeutic range. Blood levels ranged enormously, from 0.05 mg/L all the way up to 226 mg/L. In one case, a concentration of 76 mg/L was judged the likely cause of death because no other significant drugs were involved.18PubMed. Pregabalin concentrations in post-mortem blood-A two year study That case is notable because deaths attributable solely to pregabalin, without co-ingestants, are uncommon.
A separate forensic study proposed a threshold of 25 mg/L as the level above which pregabalin concentrations become “toxicologically significant,” particularly when other central nervous system depressants are present.19PubMed. Determining the Toxicological Significance of Pregabalin in Fatalities The study’s authors emphasized that existing lab protocols should be reviewed for their ability to detect pregabalin at all, since many standard toxicology screens were not originally designed to pick it up. If labs do not look for pregabalin, they will not find it, and its role in a death may go unrecognized.
Regulatory Responses and Whether They Work
Concern about misuse has prompted several countries to tighten controls on pregabalin. The United Kingdom reclassified gabapentinoids as controlled substances (Class C, Schedule 3) in April 2019, adding prescription monitoring requirements and criminal penalties for unauthorized supply. The move followed years of rising prescribing: incident gabapentin prescribing in UK primary care climbed from about 6 per 100,000 person-years in 1997–98 to a peak of roughly 625 per 100,000 in 2016–17 before beginning a downward trend even before the official reclassification took effect.20The Lancet Regional Health – Europe. Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study
Whether the reclassification itself changed prescribing behavior is a different question, and the evidence is underwhelming. An analysis of prescribing data in England found that the reclassification had negligible effects on how often general practitioners prescribed gabapentinoids, with statistical models consistent with no meaningful change after the policy took effect.21PubMed. Rescheduling gabapentinoids had negligible effects on prescribing behaviour by general practitioners in England A separate study comparing Scotland and Northern Ireland found that pregabalin prescribing actually continued to increase in Scotland over the study period, while Northern Ireland saw a decline that was attributed more to local formulary restrictions than to the UK-wide reclassification. Neither the reclassification nor pandemic lockdowns were associated with statistically significant changes in prescribing patterns in those regions.22PubMed. Impact of gabapentinoids’ reclassification policy and COVID-19 on gabapentinoids’ utilization pattern and their associated mortality in Scotland and Northern Ireland: a segmental regression analysis
In the United States, pregabalin has been a Schedule V controlled substance since its approval in 2004, the lowest level of federal control. Some U.S. states have imposed additional restrictions. Globally, the regulatory patchwork varies widely, from uncontrolled status in some countries to tighter scheduling in others, which creates opportunities for cross-border diversion.
The Healthcare Cost Dimension
Misuse of gabapentinoids does not just create medical emergencies; it drives sustained increases in healthcare spending. A U.S. analysis comparing gabapentinoid users with and without substance use disorders found that the group with addiction histories consistently ran up higher costs, even after researchers matched the two groups on other characteristics. In the matched comparison, the substance use disorder group averaged roughly $10,700 in total annual healthcare expenditures compared to about $9,200 for those without addiction histories, with the gap driven by higher outpatient visit costs, prescription spending, and home care expenses.23PubMed Central. Evaluating health-related quality of life and health resource utilization among Gabapentinoid users with substance use disorder in the US: Trends, co-prescriptions, and cost analysis The difference may not sound enormous per patient, but when multiplied across a large and growing population of gabapentinoid users with substance use problems, it represents a meaningful burden on the healthcare system.
Pregabalin and Pregnancy
A less visible but important dimension of pregabalin misuse involves pregnant women. In settings where pregabalin is widely misused, prenatal exposure is becoming a clinical concern. A case report from Algeria documented in utero exposure to pregabalin in the context of maternal drug addiction, confirming exposure through analysis of both maternal and neonatal samples. The report noted that such exposure can lead to early neonatal symptoms and potential long-term effects on the child’s development.24PubMed. In Utero Exposure to Pregabalin: Interest of Meconium Analysis – A Case Report The evidence base on fetal effects of pregabalin misuse remains thin compared to the well-studied risks of opioid or alcohol exposure during pregnancy, but the existing case literature suggests this is an area where clinical awareness is lagging behind reality.
Standard prescribing guidance already advises caution with pregabalin during pregnancy for its approved indications, and the risks are presumably amplified when the drug is taken at the higher-than-prescribed doses typical of misuse. Clinicians caring for pregnant patients with substance use disorders should be aware that pregabalin may be part of the picture even if the patient does not volunteer that information, since it often flies under the radar compared to opioids or stimulants.
Why Pregabalin Misuse Keeps Being Underestimated
Several factors conspire to keep pregabalin misuse less visible than it should be. Standard urine drug screens do not typically detect it, so it can go unnoticed in clinical and forensic settings unless a specific assay is ordered. Its scheduling as a low-tier controlled substance (or as uncontrolled in many countries) sends a cultural signal that it is relatively benign. And because it was never marketed as an anxiolytic or sedative in the way benzodiazepines were, neither patients nor prescribers may think of it in terms of addiction risk.
The self-medication pathway identified in qualitative research adds another wrinkle.25PubMed Central. Misuse of Pregabalin: a qualitative study from a patient’s perspective People who turn to pregabalin because their anxiety or pain is undertreated may not see themselves as “abusing” a drug. They see themselves as managing a condition their doctor has not adequately addressed. That framing matters not because it excuses the risks but because it points toward a practical intervention: better treatment of the underlying conditions that drive people to self-medicate in the first place. Prescribers who are reluctant to address anxiety or chronic pain directly may inadvertently push patients toward riskier alternatives, including non-prescribed pregabalin obtained online or through the street market.
For anyone currently taking pregabalin as prescribed, none of this should be read as a reason to panic or abruptly stop the medication. The drug remains effective for its approved uses in most patients. The risk picture changes substantially at supratherapeutic doses, with concomitant sedative use, or in people with addiction vulnerabilities. If you are concerned about dependence, the safest path is a gradual taper supervised by your prescriber rather than stopping cold.